Amgen, AstraZeneca post Phase 3 win for nasal polyps therapy

wildpixel/iStock via Getty Images Amgen ( NASDAQ: AMGN ) and AstraZeneca ( NASDAQ: AZN ) announced Friday that their FDA-approved asthma therapy Tezspire reached co-primary endpoints in a late-stage trial for patients with chronic rhinosinusitis with nasal polyps (CRSwNP), an inflammatory disorder affecting nasal pathways. Citing topline data from their.